Literature DB >> 17591653

Imaging of striatal dopamine release elicited with NMDA antagonists: is there anything there to be seen?

Eugenii A Rabiner1.   

Abstract

Increased release of striatal dopamine, indexed with in vivo imaging of the D(2) receptor, has been reported following an acute challenge with N-methyl-D-aspartate (NMDA) antagonist ketamine in humans. Replications of this result have not been consistently successful. The aim of this manuscript is to evaluate in vivo imaging examination of NMDA antagonism on striataL dopamine release in published reports of humans and pre-clinical species. The literature is evaluated in conjunction with insights on the effect of NMDA antagonism on dopamine release, elicited from microdialysis and tissue turnover studies, and suggestions for future studies are made.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17591653     DOI: 10.1177/0269881107077767

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  15 in total

1.  Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.

Authors:  James W Murrough; Katherine E Burdick; Cara F Levitch; Andrew M Perez; Jess W Brallier; Lee C Chang; Alexandra Foulkes; Dennis S Charney; Sanjay J Mathew; Dan V Iosifescu
Journal:  Neuropsychopharmacology       Date:  2015-03-13       Impact factor: 7.853

Review 2.  N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease.

Authors:  David Olivares; Varun K Deshpande; Ying Shi; Debomoy K Lahiri; Nigel H Greig; Jack T Rogers; Xudong Huang
Journal:  Curr Alzheimer Res       Date:  2012-07       Impact factor: 3.498

3.  Subchronic pharmacological and chronic genetic NMDA receptor hypofunction differentially regulate the Akt signaling pathway and Arc expression in juvenile and adult mice.

Authors:  Shunsuke Takagi; Darrick T Balu; Joseph T Coyle
Journal:  Schizophr Res       Date:  2015-01-12       Impact factor: 4.939

4.  Simultaneous assessment of rodent behavior and neurochemistry using a miniature positron emission tomograph.

Authors:  Daniela Schulz; Sudeepti Southekal; Sachin S Junnarkar; Jean-François Pratte; Martin L Purschke; Sean P Stoll; Bosky Ravindranath; Sri Harsha Maramraju; Srilalan Krishnamoorthy; Fritz A Henn; Paul O'Connor; Craig L Woody; David J Schlyer; Paul Vaska
Journal:  Nat Methods       Date:  2011-03-13       Impact factor: 28.547

Review 5.  A key role of the basal ganglia in pain and analgesia--insights gained through human functional imaging.

Authors:  David Borsook; Jaymin Upadhyay; Eric H Chudler; Lino Becerra
Journal:  Mol Pain       Date:  2010-05-13       Impact factor: 3.395

6.  Cognitive profile of ketamine-dependent patients compared with methamphetamine-dependent patients and healthy controls.

Authors:  Liang-Jen Wang; Chih-Ken Chen; Shih-Ku Lin; Yi-Chih Chen; Ke Xu; Ming-Chyi Huang
Journal:  Psychopharmacology (Berl)       Date:  2018-04-30       Impact factor: 4.530

7.  Interaction between effects of genes coding for dopamine and glutamate transmission on striatal and parahippocampal function.

Authors:  Andreina Pauli; Diana P Prata; Andrea Mechelli; Marco Picchioni; Cynthia H Y Fu; Christopher A Chaddock; Fergus Kane; Sridevi Kalidindi; Colm McDonald; Eugenia Kravariti; Timothea Toulopoulou; Elvira Bramon; Muriel Walshe; Natascha Ehlert; Anna Georgiades; Robin Murray; David A Collier; Philip McGuire
Journal:  Hum Brain Mapp       Date:  2012-03-22       Impact factor: 5.038

8.  Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder.

Authors:  J W Murrough; K A Collins; J Fields; K E DeWilde; M L Phillips; S J Mathew; E Wong; C Y Tang; D S Charney; D V Iosifescu
Journal:  Transl Psychiatry       Date:  2015-02-17       Impact factor: 6.222

9.  Ketamine as antidepressant? Current state and future perspectives.

Authors:  H W W Hasselmann
Journal:  Curr Neuropharmacol       Date:  2014-01       Impact factor: 7.363

10.  Gender differences in subjective discontinuation symptoms associated with ketamine use.

Authors:  Wen-Yin Chen; Ming-Chyi Huang; Shih-Ku Lin
Journal:  Subst Abuse Treat Prev Policy       Date:  2014-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.